Accepted at 7:07 p.m. Oct, 31, 2023 by dollajas
Author: revaew
Related Note: 1472091073131
Rationale for change

listing that Amiodarone shares characteristics of class 1,2, and 4 gives away that it is a class 3 by elimination.

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::^Systems::Cardio::Pharmacology #AK_Step1_v12::#Pixorize::03_Pharmacology::21_Antiarrhythmics_(New)::08_Class_III_Amiodarone #PANCE::EOR::IM #AK_Step1_v12::#SketchyPharm::02_Cardio_&_Renal::04_Antiarrhythmics::03_Class_III #AK_Step1_v12::#AMBOSS::ggaFuP #AK_Step2_v12::#AMBOSS::0w0ehR #AK_Step1_v12::#B&B::05_Cardio::04_Arrhythmias::07_Antiarrhythmic_Drugs_II #AK_Step1_v12::^Other::^HighYield::2-RelativelyHighYield #AK_Step1_v12::#OME::Clinical::04_Organ_Systems::01_Cardiology::04_Electricity::05_Anti-Arrhythmics #AK_Step1_v12::#Pixorize::03_Pharmacology::06_Cardiovascular_Pharm::11_Class_III_Antiarrhythmics-Amiodarone #AK_Step3_v12::#OME::Intern_Content::Common_Medical_Problems::AFib #AK_Step1_v12::#AMBOSS::0MaeMO #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Physeo::09_Pharm::10_Cardiac::19_Class_III_Antiarrhythmics #AK_Step2_v12::#B&B::02_Cardio::05_Pharm::01_Cardiovascular_Pharmacology_I #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#OME::04_Organ_Systems::01_Cardiology::04_Electricity::05_Anti-Arrhythmics #AK_Step1_v12::#FirstAid::07_Cardiovascular::05_Pharm::13_Antiarrhythmics-potassium_channel_blockers_(class_III) !AK_UpdateTags::Step1decks::Zanki-Pharmacology #PANCE::CARDIO::conduction_disorders/dysrhythmias #AK_Step1_v12::#Bootcamp::Cardiology::13_Antiarrhythmics::04_Class_III_Antiarrhythmics